Results 81 to 90 of about 84,630 (272)

Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice. [PDF]

, 2020
Ionising radiation (IR) is a recognised carcinogen responsible for cancer development in patients previously treated using radiotherapy, and in individuals exposed as a result of accidents at nuclear energy plants.
Adams, Cassandra J, Adams, David, Alexandrov, Ludmil B, Balmain, Allan, Del Rosario, Reyno, Fredlund, Erik, Halliwill, Kyle D, Hirst, Gillian, Iyer, Vivek, Jen, Kuang-Yu, Mamunur, Rashid, Riva, Laura, Rose Li, Yun   +12 more
core   +1 more source

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]

, 2018
The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E., Duruisseaux, M., Fernández Fernández, Agustín, Fernández Fraga, Mario, Martínez Cardús, A.   +4 more
core   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Somatic mutations render human exome and pathogen DNA more similar

, 2019
Immunotherapy has recently shown important clinical successes in a substantial number of oncology indications. Additionally, the tumor somatic mutation load has been shown to associate with response to these therapeutic agents, and specific mutational ...
Cristescu, Razvan, Ebrahimzadeh, Ehsan, Engler, Maggie, Tchamkerten, Aslan, Tse, David   +4 more
core   +1 more source

Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. [PDF]

, 2020
BackgroundMetastatic prostate cancer (PC) is highly lethal. The ability to identify primary tumors capable of dissemination is an unmet need in the quest to understand lethal biology and improve patient outcomes.
Cadaneanu, Radu M, Freeman, Michael R, Garraway, Isla P, Grasso, Catherine S, Hodge, Jennelle, Kim, Minhyung, Knudsen, Beatrice S, Kwan, Lorna, Lewis, Michael S, Li, Xinmin, Liu, Sandy T, Miller, Eric T, Quist, Michael J, Yoon, Junhee, You, Sungyong   +14 more
core  

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Modelling mutational landscapes of human cancers in vitro [PDF]

, 2014
Experimental models that recapitulate mutational landscapes of human cancers are needed to decipher the rapidly expanding data on human somatic mutations.
Alexander, J., Ardin, M., Byrnes, G., Castells, X., Hazelwood, L., Hollstein, M., Huskova, H., Marusawa, H., McKay, J., Muehlbauer, K.-R., Nedelko, T., Olivier, M., Vallée, M.P., Weninger, A., Zavadil, J.   +14 more
core   +2 more sources

Characteristics of mutational signatures of unknown etiology

NAR Cancer, 2020
Abstract Although not all somatic mutations are cancer drivers, their mutational signatures, i.e. the patterns of genomic alterations at a genome-wide scale, provide insights into past exposure to mutagens, DNA damage and repair processes.
Hu, Xiaoju, Xu, Zhuxuan, De, Subhajyoti
openaire   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source